重要提醒:2025.12.15 12:00-12:50期间发布的求助,下载出现了问题,现在已经修复完毕,请重新下载即可。如非文件错误,请不要进行驳回。

Abstract 14714: Long-Term Neurocognitive Safety of LDL-C Lowering With Evolocumab: Open-Label Extension Data From FOURIER

医学 Evolocumab公司 安慰剂 中止 情景记忆 认知功能衰退 不利影响 随机对照试验 内科学 认知 精神科 痴呆 替代医学 疾病 载脂蛋白A1 病理 胆固醇 载脂蛋白B
作者
André Zimerman,Michelle L. O’Donoghue,Xinhui Ran,KyungAh Im,Brian F Ott,François Mach,Kenton H. Zavitz,Christopher E. Kurtz,Maria Laura Monsalvo,Bei Wang,Dan Atar,Anthony Keech,Marc S. Sabatine,Robert P. Giugliano
出处
期刊:Circulation [Ovid Technologies (Wolters Kluwer)]
卷期号:148 (Suppl_1)
标识
DOI:10.1161/circ.148.suppl_1.14714
摘要

Background: Concerns have been raised about low LDL-C levels and possible adverse effects on cognition. PCSK9 inhibitors markedly lower LDL-C, yet EBBINGHAUS, a prespecified substudy within the FOURIER trial, did not show adverse cognitive changes with evolocumab over 19 months median follow-up. Purpose: To investigate the long-term effects of evolocumab on cognitive function. Methods: EBBINGHAUS was a substudy of cognitive function using the Cambridge Neuropsychological Test Automated Battery (CANTAB) within the FOURIER randomized trial of evolocumab vs placebo in patients with established ASCVD. Patients in North America and Europe who completed EBBINGHAUS on study drug were eligible for an open-label extension (OLE) study with evolocumab. The primary endpoint was change in spatial working memory strategy index of executive function score (SWMI) from baseline over time. Secondary endpoints were measures of working memory, episodic memory, and psychomotor speed. A paired t-test was used to compare baseline vs post-baseline scores during OLE. Results: Of 1204 patients from EBBINGHAUS, 306 entered the OLE and were treated with evolocumab for a median of 5.1 years. Median achieved LDL-C was 34 mg/dL (IQR 21-50). No significant change in SWMI occurred during the OLE period overall [mean (±SD) change -0.1±2.7, p=0.73] or when stratified by original randomized allocation ( Figure 1A ). For secondary outcomes, one showed no change during the OLE period, two showed small changes (10-15% of SD), but these were directionally inconsistent (one higher, one lower). In 152 patients originally randomized to evolocumab, there was no significant change in SWMI from randomization through long-term follow-up over a median of 6.7 and a maximum of 7.2 years (mean change 0.1±2.6, p=0.66) ( Figure 1B ). Conclusion: Evolocumab did not lead to any apparent long-term decline in cognitive function through follow-up extending up to 7.2 years.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
柠檬檬茶发布了新的文献求助10
刚刚
刚刚
刚刚
diaohua完成签到,获得积分10
刚刚
迷你的芒狗完成签到,获得积分20
刚刚
1秒前
林珍发布了新的文献求助10
1秒前
空巢小黄人完成签到,获得积分10
1秒前
用户253182完成签到,获得积分10
1秒前
YJJ发布了新的文献求助10
1秒前
怡然幻然完成签到,获得积分10
1秒前
1秒前
研友_VZG7GZ应助Jackie采纳,获得10
1秒前
2秒前
xxwz发布了新的文献求助10
2秒前
吉吉完成签到,获得积分10
2秒前
李周发布了新的文献求助10
2秒前
852应助好旺采纳,获得10
2秒前
Shirky发布了新的文献求助10
2秒前
3秒前
2021发布了新的文献求助10
3秒前
可耐的靖发布了新的文献求助10
4秒前
4秒前
4秒前
4秒前
5秒前
原始人完成签到,获得积分10
5秒前
三山发布了新的文献求助10
5秒前
烟花应助doranlou采纳,获得10
5秒前
5秒前
嗣音完成签到,获得积分10
5秒前
量子星尘发布了新的文献求助10
6秒前
gouqi发布了新的文献求助10
6秒前
NexusExplorer应助全都卉采纳,获得10
6秒前
6秒前
缓慢采柳完成签到 ,获得积分10
7秒前
科目三应助哈哈哈哈哈采纳,获得10
8秒前
嘿嘿发布了新的文献求助10
8秒前
8秒前
浮游应助星星采纳,获得10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
List of 1,091 Public Pension Profiles by Region 1001
On the application of advanced modeling tools to the SLB analysis in NuScale. Part I: TRACE/PARCS, TRACE/PANTHER and ATHLET/DYN3D 500
L-Arginine Encapsulated Mesoporous MCM-41 Nanoparticles: A Study on In Vitro Release as Well as Kinetics 500
Haematolymphoid Tumours (Part A and Part B, WHO Classification of Tumours, 5th Edition, Volume 11) 400
Virus-like particles empower RNAi for effective control of a Coleopteran pest 400
Unraveling the Causalities of Genetic Variations - Recent Advances in Cytogenetics 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5466602
求助须知:如何正确求助?哪些是违规求助? 4570422
关于积分的说明 14325272
捐赠科研通 4496951
什么是DOI,文献DOI怎么找? 2463624
邀请新用户注册赠送积分活动 1452586
关于科研通互助平台的介绍 1427567